Tinzaparin sodium
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tinzaparin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).[5]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | innohep(R) |
AHFS/Drugs.com | Monograph |
Routes of administration | subcutaneous (once daily) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90% for Anti-Xa activity, 67% for Anti-IIa activity)[2] |
Metabolism | minor metabolisation in liver by desulfation and/or depolymerization; excretion via kidneys in almost unchanged form |
Elimination half-life | 200 min. for Anti-Xa activity, 257. min for Anti-IIa activity [3] |
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
ECHA InfoCard | 100.110.590 |
Chemical and physical data | |
Molar mass | 6500 g/mol (average)[4] |
NY (what is this?) (verify) |
Close
It can be given subcutaneously by syringe, or intravenously.[6] It was manufactured by Leo pharmaceutical company, who withdrew the product from the US in 2011 due to low sales and a contamination issue.[7]